Skip to content
value.today
NewAmsterdam Pharma Company N.V. logo

NewAmsterdam Pharma Company N.V.

NAMS
$2.6 Bmarket cap on Oct 21, 2026+160.7% since Jan 2024
Compare
World rank
#5,496
Revenue
$23 M
For year ending December-2025
Net income
$-204 M
-905.9% margin
SEC filing
Employees
100
As of December 31, 2025
SEC filing

NewAmsterdam Pharma Company N.V. in brief

NewAmsterdam Pharma Company N.V. is a listed company in the Biotechnology industry, based in the Netherlands. Its market value was $2.6 B on 21 October 2026, which makes it the 5,496th largest listed company in the world and the 44th largest in the Netherlands on this site. In the year to December 2025 it had sales of $22 M and a net loss of $204 M. It employs about 100 people and Michael H. Davidson is its chief executive. Its shares trade under the symbol NAMS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About NewAmsterdam Pharma Company N.V.

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol lowering therapy. In multiple Phase 3 trials, we have investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Additionally, we believe that CETP inhibition may also play a role in other indications by potentially mitigating the risk of developing diseases such as Alzheimer’s disease.

From the company's annual report filed with the US SEC: read the report

NewAmsterdam Pharma Company N.V. timeline

2 events, 2022
  1. 2022
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. ✎
    Renamed NewAmsterdam Pharma Co N.V.
    Formerly NewAmsterdam Pharma Co B.V..

Events of NewAmsterdam Pharma Company N.V. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$927 M$1.9 B$2.8 B$3.7 B2023202420252026

World rank over time

▲ up 2,993 places since 2022
2022-12-25: #8503#8,50320222023-07-30: #8860#8,86020232024-01-05: #8640#8,64020242026-03-08: #1682#1,68220262026-08-01: #4819#4,81920262026-10-07: #5411#5,41120262026-10-21: #5510#5,5102026

Rank in Netherlands: #52 (Dec 2022) · #59 (Jul 2023) · #53 (Jan 2024) · #2 (Mar 2026) · #45 (Aug 2026) · #45 (Oct 2026) · #44 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
99.4×
Price / book
3.8×
Free cash flow yield
-5.7%
Net margin (TTM)
-790.2%
Operating margin
-1003.0%
Return on equity
-30.0%
Liabilities / assets
11.2%
Revenue growth
-50.6%
R&D / revenue
630.4%
Revenue per employee
$225 K
Profit per employee
$-2.0 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2021: revenue —, net income $-42M—FY21Fiscal year ending Dec 2022: revenue $103M, net income $-23M$103MFY22Fiscal year ending Dec 2023: revenue $14M, net income $-177M$14MFY23Fiscal year ending Dec 2024: revenue $46M, net income $-242M$46MFY24Fiscal year ending Dec 2025: revenue $23M, net income $-204M$23MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$23M-50.6%$-226M$-204M-905.9%
Dec 2024$46M+223.3%$-176M$-242M-530.3%
Dec 2023$14M-86.3%$-183M$-177M-1255.8%
Dec 2022$103M—$-4M$-23M-22.0%
Dec 2021——$-35M$-42M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-148M$0M$-148M$-1.72—
Dec 2024$-159M$1M$-159M$-2.56—
Dec 2023$-141M$0M$-141M$-2.15—
Dec 2022$11M$0M$10M$-1.19—
Dec 2021$-30M$0M$-30M$-3.81—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$26M
Net income, trailing 12 months
$-205M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $13M, net income $-92M$13MDec ’24Three months to Mar 2025: revenue $3M, net income $-40M$3MMar ’25Three months to Jun 2025: revenue $19M, net income $-17M$19MJun ’25Three months to Sep 2025: revenue $0M, net income $-72M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-75M$0MDec ’25Three months to Mar 2026: revenue $3M, net income $-48M$3MMar ’26Three months to Jun 2026: revenue $4M, net income $-64M$4MJun ’26Three months to Sep 2026: revenue $19M, net income $-17M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (+5374.3% on a year earlier), net income $-17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of NewAmsterdam Pharma Company N.V. with the US Securities and Exchange Commission.

Annual results

Revenue
$23 M
Operating income
$-226 M
Net income
$-204 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$769 M
Total liabilities
$86 M
Total equity
$683 M

As of December-2025

Top 100 institutional investors in NewAmsterdam Pharma Company N.V.#

As of Sep 30, 2026
183 institutions held 128.8 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 71.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in NewAmsterdam Pharma Company N.V.
#InstitutionShares heldChange (shares)% heldValueFiled
1Frazier Life Sciences Management, L.P.18,988,902+900,000 (+4.98%)15.83%$462 MNov 16, 2026
2Capital World Investors12,881,484+650,927 (+5.32%)10.74%$313 MNov 12, 2026
3FMR LLC12,116,744+1,777,081 (+17.19%)10.10%$295 MNov 10, 2026
4Ra Capital Management, L.P.9,550,1910 (0.00%)7.96%$232 MNov 16, 2026
5Janus Henderson Group Ltd.8,972,293—7.48%$218 MNov 16, 2026
6Fcpm III Services B.V.8,490,3530 (0.00%)7.08%$206 MNov 16, 2026
7Deerfield Management Company, L.P.4,254,314-10,475 (-0.25%)3.55%$103 MNov 16, 2026
8Bain Capital Life Sciences Investors, LLC3,806,559-7 (0.00%)3.17%$93 MNov 16, 2026
9Orbis Allan Gray Ltd3,760,821+2,013,194 (+115.20%)3.14%$91 MNov 16, 2026
10Duquesne Family Office LLC3,357,146+287,000 (+9.35%)2.80%$82 MNov 16, 2026
11Viking Global Investors LP2,463,911-1,739,656 (-41.39%)2.05%$60 MNov 16, 2026
12Medicxi Ventures Management (Jersey) Ltd2,182,339-26,300 (-1.19%)1.82%$53 MNov 2, 2026
13Jennison Associates LLC2,077,595-24,691 (-1.17%)1.73%$51 MNov 16, 2026
14Goldman Sachs Group Inc1,984,732+439,821 (+28.47%)1.65%$48 MNov 16, 2026
15Maverick Capital LTD1,855,630-1,412,172 (-43.21%)1.55%$45 MNov 16, 2026
16Capital International Investors1,842,170+118,675 (+6.89%)1.54%$45 MNov 12, 2026
17Alliancebernstein L.P.1,440,944+181,004 (+14.37%)1.20%$35 MNov 16, 2026
18Jpmorgan Chase & Co1,229,768+96,813 (+8.55%)1.03%$30 MNov 12, 2026
19Aberdeen Group plc1,184,091+81,306 (+7.37%)0.99%$29 MNov 10, 2026
20Price T Rowe Associates Inc /MD/1,173,316+5,959 (+0.51%)0.98%$29 MNov 16, 2026
21Two Sigma Investments, LP1,135,081+1,123,080 (+9358.22%)0.95%$28 MNov 16, 2026
22BlackRock, Inc.1,040,638-23,112 (-2.17%)0.87%$25 MNov 13, 2026
23Ameriprise Financial Inc956,961-296,588 (-23.66%)0.80%$23 MNov 16, 2026
24BNP PARIBAS ASSET MANAGEMENT Holding S.A.874,565+93,425 (+11.96%)0.73%$21 MNov 13, 2026
25Castle Hook Partners LP873,367-497,638 (-36.30%)0.73%$21 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in NewAmsterdam Pharma Company N.V.
#InstitutionShares heldChange (shares)% heldValueFiled
26Franklin Templeton Inc866,529-127,388 (-12.82%)0.72%$21 MNov 12, 2026
27Polar Capital Holdings Plc866,109-858,409 (-49.78%)0.72%$21 MNov 16, 2026
28American Century Companies Inc865,403+180,590 (+26.37%)0.72%$21 MNov 12, 2026
29Morgan Stanley836,582+260,757 (+45.28%)0.70%$20 MNov 13, 2026
30Millennium Management LLC784,158+282,544 (+56.33%)0.65%$19 MNov 16, 2026
31Woodline Partners LP752,689+200 (+0.03%)0.63%$18 MNov 16, 2026
32First Turn Management, LLC702,396+119,899 (+20.58%)0.59%$17 MNov 16, 2026
33Nwi Management LP702,0000 (0.00%)0.59%$17 MNov 13, 2026
34Adage Capital Partners GP, L.L.C.700,000+150,000 (+27.27%)0.58%$17 MNov 16, 2026
35Rock Springs Capital Management LP613,942+31,198 (+5.35%)0.51%$15 MNov 16, 2026
36TimesSquare Capital Management, LLC573,186-222,976 (-28.01%)0.48%$14 MNov 3, 2026
37Kennedy Capital Management LLC547,629+126,255 (+29.96%)0.46%$13 MNov 13, 2026
38Artia Global Partners LP503,9360 (0.00%)0.42%$12 MNov 16, 2026
39UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC457,498New0.38%$11 MNov 16, 2026
40Qube Research & Technologies Ltd373,272+326,182 (+692.68%)0.31%$9 MNov 13, 2026
41Jump Financial, LLC357,521+213,009 (+147.40%)0.30%$9 MNov 13, 2026
42Jane Street Group, LLC345,720-128,516 (-27.10%)0.29%$8 MNov 12, 2026
43Bank of New York Mellon Corp337,981-15,317 (-4.34%)0.28%$8 MNov 5, 2026
44Slate Path Capital LP319,0000 (0.00%)0.27%$8 MNov 16, 2026
45Mizuho Markets Cayman LP309,160+158,621 (+105.37%)0.26%$8 MNov 9, 2026
46Victory Capital Management Inc308,835+136,172 (+78.87%)0.26%$8 MNov 10, 2026
47Atle Fund Management AB303,824+54,976 (+22.09%)0.25%$7 MNov 12, 2026
48Bank Of America Corp /de/297,607-437,876 (-59.54%)0.25%$7 MNov 16, 2026
49Susquehanna International Group, LLP286,860-467,467 (-61.97%)0.24%$7 MNov 16, 2026
50Barclays PLC280,411+272,339 (+3373.87%)0.23%$7 MNov 6, 2026
51Citadel Advisors LLC277,982-367,823 (-56.96%)0.23%$7 MNov 16, 2026
52Affinity Asset Advisors, LLC275,0000 (0.00%)0.23%$7 MNov 13, 2026
53HRT Financial LP225,079-124,764 (-35.66%)0.19%$5 MNov 13, 2026
54Eversept Partners, LP223,962-51,509 (-18.70%)0.19%$5 MNov 16, 2026
55Wellington Management Group LLP206,477-12,272 (-5.61%)0.17%$5 MNov 16, 2026
56Deutsche Bank AG\204,457+4,526 (+2.26%)0.17%$5 MNov 6, 2026
57Ghisallo Capital Management LLC200,000New0.17%$5 MNov 16, 2026
58Vanguard Portfolio Management LLC196,630+14,956 (+8.23%)0.16%$5 MNov 13, 2026
59Peregrine Capital Management LLC192,476+22,988 (+13.56%)0.16%$5 MNov 9, 2026
60ArrowMark Colorado Holdings LLC184,214-27,629 (-13.04%)0.15%$4 MNov 16, 2026
61BNP Paribas Financial Markets183,451+147,741 (+413.72%)0.15%$4 MNov 12, 2026
62SEB Asset Management AB170,752-101,902 (-37.37%)0.14%$4 MNov 4, 2026
63Nan Fung Group Holdings Ltd164,986New0.14%$4 MNov 13, 2026
64Palo Alto Investors LP162,874+118,515 (+267.17%)0.14%$4 MNov 16, 2026
65Ishara Investments LP160,000+123,100 (+333.60%)0.13%$4 MNov 16, 2026
66Stempoint Capital LP159,044+81,455 (+104.98%)0.13%$4 MNov 16, 2026
67Alps Advisors Inc158,398+40,253 (+34.07%)0.13%$4 MNov 3, 2026
68TD Asset Management Inc148,4000 (0.00%)0.12%$4 MNov 13, 2026
69Kornitzer Capital Management Inc /KS141,711+1,778 (+1.27%)0.12%$3 MNov 3, 2026
70DCF Advisers, LLC130,868-10,132 (-7.19%)0.11%$3 MNov 4, 2026
71Swiss National Bank130,000+8,900 (+7.35%)0.11%$3 MNov 12, 2026
72State Street Corp125,780+10,565 (+9.17%)0.10%$3 MNov 12, 2026
73Geode Capital Management, LLC120,933+15,764 (+14.99%)0.10%$3 MNov 6, 2026
74ADAR1 Capital Management, LLC118,6230 (0.00%)0.10%$3 MNov 16, 2026
75Man Group plc118,313+37,481 (+46.37%)0.10%$3 MNov 16, 2026
76Balyasny Asset Management L.P.109,777New0.09%$3 MNov 16, 2026
77Swedbank AB104,1000 (0.00%)0.09%$3 MOct 27, 2026
78Cormorant Asset Management, LP100,000-400,000 (-80.00%)0.08%$2 MNov 16, 2026
79Jefferies Financial Group Inc.97,278-25,450 (-20.74%)0.08%$2 MNov 5, 2026
80Manufacturers Life Insurance Company, The96,951+719 (+0.75%)0.08%$2 MNov 13, 2026
81Northern Trust Corp91,617-2,354 (-2.51%)0.08%$2 MNov 16, 2026
82Algert Global LLC87,590+6,250 (+7.68%)0.07%$2 MNov 17, 2026
83Tudor Investment Corp Et Al85,007+5,547 (+6.98%)0.07%$2 MNov 16, 2026
84AQR Capital Management LLC78,096+55,405 (+244.17%)0.07%$2 MNov 16, 2026
85Moody Aldrich Partners LLC77,941-12,676 (-13.99%)0.07%$2 MOct 27, 2026
86Verition Fund Management LLC77,145New0.06%$2 MNov 13, 2026
87California State Teachers Retirement System74,900+7,482 (+11.10%)0.06%$2 MNov 13, 2026
88UBS Group AG71,401-272,664 (-79.25%)0.06%$2 MNov 10, 2026
89WINTON GROUP Ltd70,765New0.06%$2 MNov 12, 2026
90Pavaki Capital Management LLC66,6000 (0.00%)0.06%$2 MOct 26, 2026
91Nomura Asset Management International Inc.64,973New0.05%$2 MNov 16, 2026
92Citigroup Inc56,590+48,564 (+605.08%)0.05%$1 MNov 4, 2026
93Gsa Capital Partners LLP56,108New0.05%$1 MNov 16, 2026
94Knights of Columbus Asset Advisors LLC56,070+12,270 (+28.01%)0.05%$1 MNov 5, 2026
95Squarepoint Ops LLC50,906-41,120 (-44.68%)0.04%$1 MNov 9, 2026
96VANGUARD ASSET MANAGEMENT, Ltd48,274+5,852 (+13.79%)0.04%$1 MNov 13, 2026
97DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main44,241-19,057 (-30.11%)0.04%$1 MNov 16, 2026
98SEI Investments Co43,656+2,788 (+6.82%)0.04%$1 MNov 10, 2026
99Legal & General Group Plc43,309+3,966 (+10.08%)0.04%$1 MNov 16, 2026
100Lord, Abbett & Co. LLC42,000-264,560 (-86.30%)0.04%$1 MNov 13, 2026

All 183 institutional investors, with who bought and sold →

Superinvestors holding NewAmsterdam Pharma Company N.V.

2 of the well-known investors value.today follows, from their newest Form 13F.

Mutual funds holding NewAmsterdam Pharma Company N.V.#

117 funds in 2 countries hold shares worth $999 M (about 25.4% of the company). Since their previous reports 64 added shares and 39 sold, buying $37 M net. By country: USA 111 ($974 M), Sweden 6 ($25 M).
Mutual funds holding NewAmsterdam Pharma Company N.V.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 SMALLCAP World Fund IncSMALLCAP World Fund Inc9.27 M$314 M7.7%0.33%+10%Jun 30, 2026
🇺🇸 Strategic Advisers Fidelity U.S. Total Stock FundStrategic Advisers LLC2.01 M$68 M1.7%0.03%+38%May 31, 2026
🇺🇸 Fidelity ContrafundFidelity Management & Research Company LLC1.68 M$57 M1.4%0.03%+33%Jun 30, 2026
🇺🇸 New Economy FundCapital Research and Management Company957,477$32 M0.80%0.06%no changeMay 31, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.912,500$31 M0.76%0.26%newJun 30, 2026
🇺🇸 Select Health Care PortfolioFidelity Management & Research Company LLC690,000$23 M0.58%0.40%+3.0%May 31, 2026
🇺🇸 Capital Group U.S. Small and Mid Cap ETFCapital Research and Management Company608,660$20 M0.51%0.73%+197%May 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors566,140$19 M0.47%0.21%+5.3%Jun 30, 2026
🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC534,102$18 M0.45%1.3%no changeMay 29, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC523,700$18 M0.44%0.33%−6.9%May 31, 2026
🇺🇸 JPMorgan Small Cap Growth FundJ.P. Morgan Investment Management Inc.503,537$17 M0.42%0.65%+12%Jun 30, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.476,416$16 M0.40%1.2%+39%Jun 30, 2026
🇺🇸 Columbia Small Cap Growth FundColumbia Funds Series Trust I445,889$15 M0.37%0.41%newMay 31, 2026
🇺🇸 Small Cap Growth FundAmerican Century Investment Management, Inc.524,241$15 M0.44%0.26%+21%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC504,110$14 M0.42%0.16%no changeJul 31, 2026
🇺🇸 Fidelity Stock Selector Small Cap FundFidelity Management & Research Company LLC471,600$13 M0.39%0.18%+16%Jul 31, 2026
🇺🇸 abrdn World Healthcare Fundabrdn Inc.382,193$13 M0.32%2.3%+13%Jun 30, 2026
🇺🇸 Fidelity Advisor Biotechnology FundFidelity Management & Research Company LLC448,000$12 M0.37%0.57%−24%Jul 31, 2026
🇺🇸 Columbia Acorn FundColumbia Management Investment Advisers, LLC363,308$12 M0.30%0.44%no changeJun 30, 2026
🇺🇸 Fidelity Contrafund K6Fidelity Management & Research Company LLC361,718$12 M0.30%0.03%+32%Jun 30, 2026
🇺🇸 Fidelity Advisor Health Care FundFidelity Management & Research Company LLC420,000$12 M0.35%0.37%+20%Jul 31, 2026
🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P.292,628$10 M0.24%0.32%−4.7%Jun 30, 2026
🇺🇸 AB Discovery Growth Fund, Inc.AllianceBernstein L.P.289,630$10 M0.24%0.34%−0.5%Jun 30, 2026
🇺🇸 Harbor Small Cap Growth FundHarbor Capital Advisors, Inc.344,443$10 M0.29%0.36%−27%Jul 31, 2026
🇸🇪 SEB LäkemedelsfondSEB Funds AB272,654$9 M0.23%0.51%no changeJun 30, 2026
🇺🇸 SMALLCAP World FundCapital Research and Management Company257,315$9 M0.21%0.34%newJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.244,176$8 M0.20%1.2%+55%Jun 30, 2026
🇺🇸 Fidelity FundFidelity Management & Research Company LLC243,800$8 M0.20%0.09%no changeJun 30, 2026
🇺🇸 Franklin Small Cap Growth FundFranklin Advisers, Inc.292,360$8 M0.24%0.33%−1.5%Jul 31, 2026
🇺🇸 Fidelity Series Small Cap Opportunities FundFidelity Management & Research Company LLC270,700$8 M0.23%0.16%−5.2%Jul 31, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC250,980$7 M0.21%0.15%no changeJul 31, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.174,388$6 M0.15%0.28%+6.0%Jun 30, 2026
🇺🇸 Victory Pioneer Disciplined Growth FundVictory Capital Management Inc.172,663$6 M0.14%0.25%newMay 31, 2026
🇺🇸 BNY Mellon Small/Mid Cap Growth FundBNY Mellon Investment Funds I162,575$6 M0.14%0.64%−8.9%Jun 30, 2026
🇺🇸 JPMorgan Small Cap Blend FundJ.P. Morgan Investment Management Inc.162,503$6 M0.14%0.33%+12%Jun 30, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.187,726$5 M0.16%0.45%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Discovery FundFidelity Management & Research Company LLC183,400$5 M0.15%0.22%+23%Jul 31, 2026
🇺🇸 VIP Health Care PortfolioFidelity Management & Research Company LLC140,000$5 M0.12%0.41%+22%Jun 30, 2026
🇺🇸 Buffalo Mid Cap Discovery FundKornitzer Capital Management, Inc.138,948$5 M0.12%1.4%newJun 30, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.135,312$5 M0.11%0.02%−0.2%May 31, 2026
🇸🇪 HealthInvest Small & Mid Cap HealthcareAtle Fund Management AB131,396$4 M0.11%3.5%+48%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Discovery FundFidelity Management & Research Company LLC157,200$4 M0.13%0.22%+20%Jul 31, 2026
🇺🇸 Putnam Global Health Care FundPutnam Investment Management, LLC120,500$4 M0.10%0.28%+5.8%May 31, 2026
🇺🇸 Fidelity Advisor Small Cap FundFidelity Management & Research Company LLC119,300$4 M0.10%0.17%no changeMay 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.118,514$4 M0.10%2.5%+17%May 31, 2026
🇸🇪 HealthInvest Sustainable HealthcareAtle Fund Management AB117,452$4 M0.10%1.1%+41%Jun 30, 2026
🇺🇸 American Funds U.S. Small & Mid Cap Equity FundAmerican Funds U.S. Small & Mid Cap Equity Fund116,333$4 M0.10%0.57%+238%May 31, 2026
🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company140,000$4 M0.12%0.08%no changeJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC110,693$4 M0.09%0.17%+20%Jun 30, 2026
🇺🇸 Fidelity Series Small Cap Core FundFidelity Management & Research Company LLC134,200$4 M0.11%0.24%+24%Jul 31, 2026
🇸🇪 Swedbank Robur HealthcareSwedbank Robur Fonder AB104,100$4 M0.09%0.23%+3.2%Jun 30, 2026
🇸🇪 Handelsbanken Hälsovård TemaHandelsbanken Fonder AB100,000$3 M0.08%0.14%−75%Jun 30, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.91,871$3 M0.08%0.36%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC111,035$3 M0.09%0.12%+27%Jul 31, 2026
🇺🇸 Eaton Vance Worldwide Health Sciences FundEaton Vance Management81,652$3 M0.07%0.36%no changeMay 31, 2026
🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC79,983$3 M0.07%0.23%−8.9%May 29, 2026
🇺🇸 Fidelity Small Cap Stock FundFidelity Management & Research Company LLC94,531$3 M0.08%0.20%+128%Jul 31, 2026
🇺🇸 Columbia Variable Portfolio - Acorn FundColumbia Management Investment Advisers, LLC69,887$2 M0.06%0.44%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC70,289$2 M0.06%<0.01%+3.4%May 31, 2026
🇺🇸 Allspring Small Company Growth FundAllspring Funds Management, LLC78,861$2 M0.07%0.43%−1.3%Jul 31, 2026
🇺🇸 Small Cap Equity FundGuideStone Capital Management, LLC60,383$2 M0.05%0.20%+15%Jun 30, 2026
🇺🇸 Optimum Small-Mid Cap Growth FundDelaware Management Company58,613$2 M0.05%0.21%−3.7%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.57,600$2 M0.05%0.26%newJun 30, 2026
🇺🇸 Large-Cap Growth PortfolioPacific Life Fund Advisors LLC55,796$2 M0.05%0.13%+5.9%Jun 30, 2026
🇺🇸 Lord Abbett Micro-Cap Growth FundLord, Abbett & Co. LLC65,889$2 M0.05%0.86%+68%Jul 31, 2026
🇺🇸 Meridian Small Cap Growth FundArrowMark Colorado Holdings, LLC53,374$2 M0.04%0.66%no changeJun 30, 2026
🇺🇸 Multi-Manager Small Cap Equity Strategies FundColumbia Funds Series Trust I53,618$2 M0.04%0.14%−20%May 31, 2026
🇺🇸 Lord Abbett International Opportunities FundLord, Abbett & Co. LLC60,000$2 M0.05%0.50%+43%Jul 31, 2026
🇺🇸 Mercer US Small/Mid Cap Equity FundMercer Investments LLC45,790$2 M0.04%0.08%−32%Jun 30, 2026
🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC45,506$2 M0.04%<0.01%−55%May 31, 2026
🇺🇸 AMG TimesSquare Small Cap Growth FundAMG Funds LLC42,974$1 M0.04%1.3%—Jun 30, 2026
🇺🇸 Fidelity Fundamental Small-Mid Cap ETFFidelity Management & Research Company LLC49,856$1 M0.04%0.09%+17%Jul 31, 2026
🇺🇸 Inception PortfolioMorgan Stanley Investment Management Inc.40,364$1 M0.03%0.48%+164%Jun 30, 2026
🇺🇸 Empower Small Cap Growth FundEmpower Capital Management, LLC39,647$1 M0.03%0.52%+0.7%Jun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company46,400$1 M0.04%0.05%−51%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC34,423$1 M0.03%0.01%+1.7%May 31, 2026
🇺🇸 Knights of Columbus Small Cap Equity FundKnights of Columbus Asset Advisors LLC40,016$1 M0.03%0.53%+22%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC32,536$1 M0.03%0.50%+73%Jun 30, 2026
🇺🇸 iShares ESG Aware MSCI USA Small-Cap ETFBlackRock Fund Advisors32,510$1 M0.03%0.05%+15%May 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC31,311$1 M0.03%0.22%+387%Jun 30, 2026
🇺🇸 Columbia Variable Portfolio - Small Company Growth FundColumbia Management Investment Advisers, LLC30,325$1 M0.03%0.39%+109%Jun 30, 2026
🇺🇸 Small Cap Growth FundThe Variable Annuity Life Insurance Company28,262$1 M0.02%0.18%−5.9%May 31, 2026
🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC26,479$1 M0.02%0.03%−68%Jun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC28,680$1 M0.02%0.02%+35%Jul 31, 2026
🇺🇸 Franklin Alternative Strategies FundFranklin Advisers, Inc.23,134$1 M0.02%0.13%—May 29, 2026
🇸🇪 Handelsbanken Global Småbolag Index CriteriaHandelsbanken Fonder AB22,400$1 M0.02%0.03%+19%Jun 30, 2026
🇺🇸 Catholic Responsible Investments Small-Mid Cap Equity FundChristian Brothers Investment Services, Inc.25,180$1 M0.02%0.12%newJul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC20,200$1 M0.02%0.27%newJun 30, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC19,307$1 M0.02%0.09%−1.7%May 31, 2026
🇺🇸 U.S. Small and Mid Cap Equity FundCapital Research and Management Company18,143$1 M0.02%0.56%—Jun 30, 2026
🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC15,720$1 M0.01%0.17%−2.3%Jun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC19,093$1 M0.02%0.05%+29%Jul 31, 2026
🇺🇸 VIP Contrafund PortfolioFidelity Management & Research Company LLC15,500$1 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 BNY Mellon Small Cap Multi-Strategy FundBNY Mellon Investment Adviser, Inc.15,063$1 M0.01%0.39%−13%May 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC14,300$0 M0.01%0.27%newJun 30, 2026
🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P.16,480$0 M0.01%0.13%—Apr 30, 2026
🇺🇸 Fidelity Advisor New Insights FundFidelity Management & Research Company LLC13,400$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Putnam VT Global Health Care FundPutnam Investment Management, LLC11,600$0 M<0.01%0.27%newJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.11,035$0 M<0.01%0.09%newJun 30, 2026
🇺🇸 AVIP Fidelity Institutional AM Equity Growth PortfolioCONSTELLATION INVESTMENTS INC9,903$0 M<0.01%0.14%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at NewAmsterdam Pharma Company N.V.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$227 K
1 purchase, 1 insider
Sold, 12 months
$63.3 M
43 sales, 6 insiders
Net, 12 months
-$63.0 M
open market only
Insiders on file
20
since
$237 K-$28.7 M$0Feb 2024: bought $95 K (1 trades), sold $0 (0 trades)Feb 24Mar 2024: bought $181 K (1 trades), sold $4.1 M (1 trades)Jun 2024: bought $86 K (1 trades), sold $0 (0 trades)Aug 2024: bought $81 K (1 trades), sold $0 (0 trades)Sep 2024: bought $17 K (1 trades), sold $0 (0 trades)SepOct 2024: bought $0 (0 trades), sold $707 K (1 trades)Nov 2024: bought $0 (0 trades), sold $1.3 M (4 trades)Dec 2024: bought $0 (0 trades), sold $28.7 M (21 trades)Jan 2025: bought $0 (0 trades), sold $0 (11 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $0 (2 trades)Mar 2025: bought $110 K (2 trades), sold $3.1 M (4 trades)Apr 2025: bought $0 (0 trades), sold $0 (2 trades)May 2025: bought $0 (0 trades), sold $0 (1 trades)MayJun 2025: bought $237 K (3 trades), sold $1.9 M (2 trades)Jul 2025: bought $0 (0 trades), sold $2.1 M (3 trades)Aug 2025: bought $11 K (1 trades), sold $2.7 M (4 trades)Sep 2025: bought $47 K (2 trades), sold $4.3 M (3 trades)SepDec 2025: bought $0 (0 trades), sold $5.2 M (3 trades)Jan 2026: bought $0 (0 trades), sold $8.5 M (15 trades)Feb 2026: bought $0 (0 trades), sold $12.2 M (9 trades)Mar 2026: bought $0 (0 trades), sold $26.0 M (7 trades)MarMay 2026: bought $0 (0 trades), sold $2.3 M (1 trades)Jun 2026: bought $0 (0 trades), sold $1.2 M (2 trades)Jul 2026: bought $0 (0 trades), sold $3.2 M (3 trades)Aug 2026: bought $0 (0 trades), sold $3.4 M (1 trades)AugSep 2026: bought $227 K (1 trades), sold $1.3 M (2 trades)
Bought (open market)Sold (open market)Hover a month for the totals
NewAmsterdam Pharma Company N.V.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorOption exercise10b5-1 plan · indirect+50,246——119,548Form 4
filed Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorSell10b5-1 plan · indirect-50,246$25.03$1.3 M69,302Form 4
filed Michael H. DavidsonChief Executive Officer, DirectorBuy+10,000$22.65$227 K792,923Form 4
filed John W. SmitherDirectorSell-1,600$25.32$41 K8,760Form 4
filed Robert William GunningVice President, ControllerGrant or award+3,200——3,200Form 4
filed Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorOption exercise10b5-1 plan · indirect+125,000——194,302Form 4
filed Kastelein Johannes Jacob PieterChief Scientific Officer, DirectorSell10b5-1 plan · indirect-125,000$26.91$3.4 M69,302Form 4
filed Louise Frederika KooijChief Accounting OfficerOption exercise10b5-1 plan+25,000$11.90$298 K49,353Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: NewAmsterdam Pharma Company N.V.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
12.0 M
10.5% of shares · 8.32 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2024-12-10 11:55 UTC, code T3, resumed 12:30 UTC
  • 2024-11-20 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 2,466 shares at $21.50
  • : 1,038 shares at $20.62
  • : 442 shares at $22.27
  • : 36,694 shares at $24.16
  • : 1,953 shares at $24.32

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

NewAmsterdam Pharma Company N.V. scorecard#

Passes 2 of the 16 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 21, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.8×Price to book 3.8× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median99.4×Price to sales 99.4× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-5.7%Free cash flow is -5.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 4
    • ✗Revenue grew in the newest year-50.6%Revenue down 50.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-39.7%-39.7% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-39.7%-39.7% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-1.72 vs -2.56Diluted EPS -1.72 in fiscal 2025 against -2.56 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$204 MNet income -$204 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-28.3%-28.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities7.9×Current ratio 7.88 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone16.61Z-score 16.61 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year25.5%Diluted shares up 25.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from NewAmsterdam Pharma Company N.V.'s statements, beside the median of Biotechnology.

NewAmsterdam Pharma Company N.V.: main financial ratios in 2025
Ratio2025Median of peers
Net margin-905.9%-68.9%
Return on equity-28.3%-61.0%
Revenue growth, 3 years a year-39.7%12.9%
Revenue growth-50.6%15.8%
Free cash flow margin-657.9%-61.5%

2of 7on the Piotroski tests of financial strength

  • Revenue fell 50.6% against the year before.
  • Net loss of $204 million, the 5th loss-making year in a row.
  • Free cash flow was negative: -$148 million.
  • The share count rose 25.5% in the year.

NewAmsterdam Pharma Company N.V.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

NewAmsterdam Pharma Company N.V.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025 · USDFY 2024to Dec 31, 2024 · USDFY 2023to Dec 31, 2023 · USDFY 2022to Dec 31, 2022 · EURFY 2021to Dec 31, 2021 · EURFY 2020to Dec 31, 2020 · EUR
Income statement
Revenue23461498——
Research and development14215115982254.0
Selling, general and administrative1067038224.81.4
General and administrative151416———
Operating expenses248222197———
Total costs and expenses———165305.4
Operating income−226−176−183−68−30−5.4
Interest and finance income2817110.00.0—
Interest expense and finance costs———0.30.20.3
Income before tax−204−242−177−78−29−5.7
Income tax—−0.00.0———
Net income including minority interests−204−242−177−78−29−5.7
Net income attributable to shareholders−204−242−177−78r−29r−5.7r
Earnings per share, basic-1.72-2.56-2.15-1.97r-1.21r-0.62r
Earnings per share, diluted-1.72-2.56-2.15-1.97r-1.21r-0.62r
Shares, weighted average (basic)118948219r119.2r
Shares, weighted average (diluted)118948219114.3r
Balance sheet
Cash and cash equivalents490772340439537.9
Short-term investments14662————
Other current assets38246.3———
Current assets67686334744859—
Property, plant and equipment0.40.20.00.10.20.0
Right-of-use (leased) assets0.20.40.10.10.2—
Other intangible assets———83——
Non-current assets———830.9—
Total assets76986534753260—
Accounts payable9.04.717199.8—
Current liabilities8610750359.9—
Lease liabilities (non-current)0.10.2—0.10.1—
Non-current liabilities———120.1—
Total liabilities8610759———
Retained earnings−762−559−317———
Shareholders' equity683758288———
Total equity———48550−3.6
Total liabilities and equity76986534753260—
Shares outstanding114108r8282115.0
Cash-flow statement
Depreciation and amortization0.20.10.00.10.00.0
Share-based compensation5934253.91.0—
Cash from operating activities−148−159−1418.0−25−6.0
Capital expenditure−0.2−0.7−0.0−0.0−0.0−0.0
Cash from investing activities−175−63−0.00.7−0.0−0.0
Debt issued—————11
Debt repaid———−0.7——
Cash from financing activities306608.93756911
Exchange-rate effect on cash———1.61.40.0
Report10-K10-K10-K20-F/A20-F/A20-F/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where NewAmsterdam Pharma Company N.V. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (2 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
NewAmsterdam Pharma Company N.V.: countries of operation
CountryPresenceRevenue there
🇳🇱 NetherlandsHeadquarters1 office1 subsidiary—
🇺🇸 USA1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at NewAmsterdam Pharma Company N.V.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$13.6 M
Michael Davidson, M.D.
Other top executives, average
$4.3 M
the CEO earned 3.2× this
$100 invested is now
$322
peer group: $135
NewAmsterdam Pharma Company N.V.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Michael Davidson, M.D.$13.6 M$30.5 M$4.3 M$322 (peers $135)
2024Michael Davidson, M.D.$6.5 M$49.5 M$2.6 M$236 (peers $104)
2023Michael Davidson, M.D.$5.8 M$4.7 M$3.3 M$102 (peers $105)

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at NewAmsterdam Pharma Company N.V.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 2 · Shareholder vote 2 · Results announced 8

NewAmsterdam Pharma Company N.V.: events reported to the SEC
FiledWhat happenedFiling
Directors and officers8-K
Directors and officers8-K/A
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026

Acquisitions and funding#

1 acquisitions

Businesses it acquired

Acquisitions by NewAmsterdam Pharma Company N.V.
AcquiredAcquisition dateCompletionPriceStakeSource
NewAmsterdam Pharma Holding B.V. and NewAmsterdam Pharma Investment CorporationJul 2022———Annual report

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Discuss NewAmsterdam Pharma Company N.V.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 117 funds hold $999 millionautomatic update · Jul 31, 2026

    117 mutual funds in 2 countries hold shares of NewAmsterdam Pharma Company N.V. worth $999 million, about 25.4% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 64 funds added shares and 39 sold; on balance they bought $37 million. Share splits are not counted as trading.

How NewAmsterdam Pharma Company N.V. compares in Biotechnology

  • Market cap$2.6 B · higher than 83% of 726
  • Revenue$23 M · higher than 51% of 647
  • Net margin-790.2% · higher than 3% of 408
  • Revenue growth-50.6% · higher than 18% of 438
  • Price / sales99.4× · lower than 9% of 339
  • Price / book3.8× · lower than 40% of 534
  • FCF yield-5.7% · higher than 69% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
NewAmsterdam Pharma Company N.V.🇳🇱$2.6 B—-790.2%-50.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 21, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at NewAmsterdam Pharma Company N.V.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show NewAmsterdam Pharma Company N.V.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about NewAmsterdam Pharma Company N.V.? Suggest a correction